Heart Problems: Investigating the Cardiac Side Effects of Cancer Treatments
In June, approximately 100 researchers attended a workshop on the campus of the National Institutes of Health (NIH) in Bethesda, MD, about an important but underappreciated side effect of some treatments for cancer: heart problems.
Higher Risk of Heart Failure Seen in Some Cancers
Some people who have been treated for breast cancer or lymphoma have a higher risk of developing congestive heart failure than people who haven't had cancer, results from a new study show.
The study researchers retrospectively compared heart failure rates in people who were diagnosed with breast cancer or lymphoma with those in people who did not have cancer.
Encouraging A Single Core Lab for Echocardiogram Results
This article summarizes a study funded by the NCI Division of Cancer Prevention to determine the reproducibility of cardiac safety assessments across two academic echocardiography core laboratories (ECLs), (Duke and the University of Pennsylvania), for echocardiograms (ECHOs) obtained in trials active in the community oncology setting.
Study Identifies Potential Cause of Hearing Loss from Cisplatin
Results from a new study may explain why many patients treated with the chemotherapy drug cisplatin develop lasting hearing loss.
Researchers found that, in both mice and humans, cisplatin can be found in the cochlea—the part of the inner ear that enables hearing—months and even years after treatment. By contrast, the drug is eliminated from most organs in the body within days to weeks after being administered.
Acupuncture May Reduce Treatment-Related Joint Pain for Breast Cancer Patients
Acupuncture can reduce joint pain caused by drugs called aromatase inhibitors, according to results from a large, rigorous study of this approach in postmenopausal women with early-stage breast cancer.
Heart Attack, Stroke Risk May Be Elevated Following Cancer Diagnosis
A diagnosis of cancer can come with an increased risk of a heart attack or stroke in the months following the diagnosis, findings from a new study suggest.
In a clinical trial involving patients with metastatic cancer, administration of zoledronic acid every 12 weeks was as effective at preventing skeletal-related events caused by bone metastases as administration every 4 weeks.
Pre-Application Webinars for RFA-CA-17-052
"Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability (U01)"
NCI Listens — Slides Available
Materials are now available from NCI Listens: Identifying Opportunities for Symptom Management Research in Response to Blue Ribbon Report (PPT, 1.44MB), a webinar lead by Dr. Ann O’Mara, Head, Palliative Care Research in the Division of Cancer Prevention (DCP), and other DCP staff, DCP was interested in hearing from the extramural research and patient advocate community regarding knowledge gaps and priorities for symptom management research, particularly as it pertains to understanding the mechanisms of cancer and treatment related symptoms and adverse events/toxicities that patients report when enrolled in clinical trials.